406 related articles for article (PubMed ID: 30134537)
1. Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability.
Gigliobianco MR; Casadidio C; Censi R; Di Martino P
Pharmaceutics; 2018 Aug; 10(3):. PubMed ID: 30134537
[TBL] [Abstract][Full Text] [Related]
2. Nanocrystals Technology for Improving Bioavailability of Poorly Soluble Drugs: A Mini-Review.
Zhou Y; Du J; Wang L; Wang Y
J Nanosci Nanotechnol; 2017 Jan; 17(1):18-28. PubMed ID: 29616786
[TBL] [Abstract][Full Text] [Related]
3. Functional and Modified Nanocrystals Technology for Target Drug Delivery.
Zhao J; Liu Y; Wang L; Zhou Y; Du J; Wang Y
J Nanosci Nanotechnol; 2018 Aug; 18(8):5207-5221. PubMed ID: 29458570
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in the use of nanocrystals to improve bioavailability of APIs.
Ding Y; Zhao T; Fang J; Song J; Dong H; Liu J; Li S; Zhao M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1958. PubMed ID: 38629192
[TBL] [Abstract][Full Text] [Related]
5. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
[TBL] [Abstract][Full Text] [Related]
6. Supercritical carbon dioxide-based technologies for the production of drug nanoparticles/nanocrystals - A comprehensive review.
Padrela L; Rodrigues MA; Duarte A; Dias AMA; Braga MEM; de Sousa HC
Adv Drug Deliv Rev; 2018 Jun; 131():22-78. PubMed ID: 30026127
[TBL] [Abstract][Full Text] [Related]
7. Nanocrystal Technology as a Strategy to Improve Drug Bioavailability and Antitumor Efficacy for the Cancer Treatment.
Fan M; Geng S; Liu Y; Wang J; Wang Y; Zhong J; Yan Z; Yu L
Curr Pharm Des; 2018; 24(21):2416-2424. PubMed ID: 29766787
[TBL] [Abstract][Full Text] [Related]
8. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs.
Gao L; Liu G; Ma J; Wang X; Zhou L; Li X; Wang F
Pharm Res; 2013 Feb; 30(2):307-24. PubMed ID: 23073665
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical Strategies for Stabilizing Drug Nanocrystals.
Yang H; Kim H; Jung S; Seo H; Nida SK; Yoo SY; Lee J
Curr Pharm Des; 2018; 24(21):2362-2374. PubMed ID: 29766785
[TBL] [Abstract][Full Text] [Related]
10. Nanosizing of drugs: Effect on dissolution rate.
Dizaj SM; Vazifehasl Zh; Salatin S; Adibkia Kh; Javadzadeh Y
Res Pharm Sci; 2015; 10(2):95-108. PubMed ID: 26487886
[TBL] [Abstract][Full Text] [Related]
11. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability.
Morakul B; Suksiriworapong J; Leanpolchareanchai J; Junyaprasert VB
Int J Pharm; 2013 Nov; 457(1):187-96. PubMed ID: 24076396
[TBL] [Abstract][Full Text] [Related]
12. Nanocrystals: An Overview of Fabrication, Characterization and Therapeutic Applications in Drug Delivery.
Pardhi VP; Verma T; Flora SJS; Chandasana H; Shukla R
Curr Pharm Des; 2018; 24(43):5129-5146. PubMed ID: 30767737
[TBL] [Abstract][Full Text] [Related]
13. New method for the effective production of ultrafine drug nanocrystals.
Möschwitzer J; Müller RH
J Nanosci Nanotechnol; 2006; 6(9-10):3145-53. PubMed ID: 17048530
[TBL] [Abstract][Full Text] [Related]
14. Nanocrystals Technology for Pharmaceutical Science.
Cheng Z; Lian Y; Kamal Z; Ma X; Chen J; Zhou X; Su J; Qiu M
Curr Pharm Des; 2018; 24(21):2497-2507. PubMed ID: 29773056
[TBL] [Abstract][Full Text] [Related]
15. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery.
Pawar VK; Singh Y; Meher JG; Gupta S; Chourasia MK
J Control Release; 2014 Jun; 183():51-66. PubMed ID: 24667572
[TBL] [Abstract][Full Text] [Related]
16. Nanocrystal for ocular drug delivery: hope or hype.
Sharma OP; Patel V; Mehta T
Drug Deliv Transl Res; 2016 Aug; 6(4):399-413. PubMed ID: 27165145
[TBL] [Abstract][Full Text] [Related]
17. Dissolution study of nanocrystal powders of a poorly soluble drug by UV imaging and channel flow methods.
Sarnes A; Østergaard J; Jensen SS; Aaltonen J; Rantanen J; Hirvonen J; Peltonen L
Eur J Pharm Sci; 2013 Nov; 50(3-4):511-9. PubMed ID: 23999036
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory drug nanocrystals: state of art and regulatory perspective.
Macedo LO; Barbosa EJ; Löbenberg R; Bou-Chacra NA
Eur J Pharm Sci; 2021 Mar; 158():105654. PubMed ID: 33253884
[TBL] [Abstract][Full Text] [Related]
19. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
Leone F; Cavalli R
Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
[TBL] [Abstract][Full Text] [Related]
20. Understanding Critical Quality Attributes for Nanocrystals from Preparation to Delivery.
Peltonen L; Strachan C
Molecules; 2015 Dec; 20(12):22286-300. PubMed ID: 26703528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
